Salvage Autologous Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma: Long-Term Efficacy and Safety Outcomes from a Single-Center Real-World Cohort
Gulten Korkmaz, Funda Ceran, Simten Dagdas, Sertan Akgun, Kerim Kızılkaya, Ahmet Ceylan, Fahir Ozturk, Muruvvet Seda Aydın, Emel Isleyen, Merve Ecem Erdogan Yon, Gulsum Ozet · 2026
Read Salvage Autologous Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma: Long-Term Efficacy and Safety Outcomes from a Single-Center Real-World Cohort by Gulten Korkmaz, Funda Ceran, Simten Dagdas, Sertan Akgun, Kerim Kızılkaya, Ahmet Ceylan, Fahir Ozturk, Muruvvet Seda Aydın, Emel Isleyen, Merve Ecem Erdogan Yon, Gulsum Ozet (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13607328.txt.
Description
A team of doctors in Turkey reports long term results for a second stem cell transplant in blood cancer care. Their 2026 paper looks at people with multiple myeloma whose disease came back or did not respond to care. The group works at one center and studied its own past cases.
The team reviewed 57 people who had the second transplant from 2012 to 2025. Half had a strong response before the transplant, and four in five had one by day 100 after it. Deaths linked to the transplant were low, though infections were common. On average, people lived years after the transplant, and blood test values helped predict who did best.
Catalog record
| CREATOR | Gulten Korkmaz, Funda Ceran, Simten Dagdas, Sertan Akgun, Kerim Kızılkaya, Ahmet Ceylan, Fahir Ozturk, Muruvvet Seda Aydın, Emel Isleyen, Merve Ecem Erdogan Yon, Gulsum Ozet |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |